Get all your news in one place.
100’s of premium titles.
One app.
Start reading

India's first intranasal Covid vaccine by Bharat Biotech gets DCGI approval

India's first intranasal Covid vaccine by Bharat Biotech gets DCGI approval (AFP)

Mandaviya tweeted, Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.

Last month after completing the phase-III and booster dose trials for its intranasal Covid-19 vaccine, Bharat Biotech said it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India.

It has proven to be safe, well-tolerated and immunogenic in subjects in controlled trials, BBIL said in a statement.

The data from both Phase III human clinical trials have been submitted for approval to national regulatory authorities, the company said.

"If approved, this intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy to administer formulation and delivery device. Vectored vaccines also enable faster development of targeted vaccines in response to emerging variants of concern," Bharat Biotech joint managing director Suchhitra K Ella said.

(With inputs from agencies)

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Post your comment
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.